Blood levels of CCK peptides relative to panic disorder treatmen

Details Blood levels of CCK peptides relative to panic disorder treatmen Blood levels of CCK peptides relative to panic disorder treatmen

1994-11-18

1996-09-24

Kight, John

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

435 23, 435 24, 436 16, 436 86, 436 74, 436 63, 514 2, 530300, 530302, 530314, 530417, 210656, C12Q 100, C12Q 137, G01N 3100, A61K 3800

Patent

active

055589871

ABSTRACT:
A method of treating a patient having a panic disorder, the patient having an elevated CCK peptide plasma level, by lowering the plasma CCK peptide level of the patient. A further method provides a diagnosis of panic disorder in a patient by detecting if that patient's plasma contains elevated CCK peptide levels. A further method determines the efficacy of the drug for the treatment of panic disorder by detecting the ability of the drug to lower elevated CCK peptide levels in a model for panic disorder. Additionally, a method of dosing a patient having elevated CCK peptide levels with an antipanic disorder drug is characterized by administering the drug to a patient and monitoring the lowering of the elevated plasma CCK peptide levels of the patient.

REFERENCES:
patent: 4508726 (1985-04-01), Coleman
patent: 4634703 (1987-01-01), Kurtz et al.
patent: 4794103 (1988-12-01), Bertolini
patent: 5166151 (1992-11-01), Freidinger et al.
Chem Abstract, vol. 111(13:108885 S (Robinson et al).
Woodruff et al, "Annu. Rev. Pharm. Toxicol.", vol. 31, pp. 469-501, (1991).
Bradwejn et al, "Arch Gen Psy", pp. 603-610, (1991).
Savter et al; J. Chromatography, 297:215-223 (1984).
Bibb et al; "Behav. Res. Ther.", 24:49-58; Alcohol Use & Abuse Among Diagnosed Agoraphobics; (1986).
Passaro et al; "Brain Research"; 241:335-340; Rapid Appearance of Intraventricularly Administered Neuropeptides in Peripheral Circulation; (1982).
Chen et al, (Abstract), "Drug Metab Dispos", 20(3),(1992) p. 390.
Klerman, G. L., Weissman, M. M., Ouellette, R., Johnson, J. and Greenwald, S. JAMA 256, 742-746 (1991).
White, P. D. & Jones, T. D. New Eng. Am. Heart J. 3, 302-318 (1928).
Wood, P. Br. Med. J. 1, 767-772, 805-822, 845-851 (1941).
Wheeler, E. O., White, P. D., Reed, E. W., & Cohen, M. E. JAMA 142, 878-889 (1950).
Marks, I. & Lader, M. J. Nerv. Ment. Dis. 156, 3-18 (1973).
Robins, L. N. Helzer, J. E., Weissman, M. M. et al. Arch. Gen. Psychiatr. 41, 949-958 (1984).
Sheehan, D. V., Sheehan, K. E., & Minichello, W. E. Compr. Psychiatr. 22, 544-553 (1981).
Torgersen, S. Arch. Gen. Psychiatr.40, 1085-1089 (1983).
McNair, D. M. Kahn, R. J. in Anxiety: New Research and Changing Concepts (eds. Klein, D. F. & Rabkin, J.) 69-79 (Raven, New York 1981).
Crowe, R. R., Pauls, D. L. Slymen, D. J., Noyes, R. Am. J. Hum. Genetics 32, 639-644 (1980).
Pauls, D. L., Bocher, K. D., Crowe, R. R. et al. Am. J. Hum. Genet. 32, 639-644 (1980).
Crowe, R. R., Noyes, R., Wilson, A. F. et al. Arch. Gen. Psychiatr. 44, 933-937 (1987).
Liberthson, R., Sheehan, D. V., King, M. E. et al. Am. J. Psychiatr. 143, 511-515 (1986).
Noyes, R., Clancy, J., Hoenk, P. R., & Slymen, D. J. Comp. Psychiatr. 19, 407-413 (1978).
Coryell, W., Noyes, R., & Clancy, J. Arch. Gen. Psychiatr. 39, 701-703 (1982).
Bradwejn, J., Koszycki, B. & Shriqui, C. Arch. Gen. Psychiatr. 48, 603-610 (1991).
Bradwejn, J. & de Montigny, C. Nature 312, 363-364 (1984).
Sheehan, D. V. Drug Therapy 12, 49 (1982).
Sheehan, D. V., Coleman, J. H., Greenblatt, D. J., Jones, K. J., Levine, & P. H. et al. J. Clin. Psychopharmac. 4, 66-75 (1984).
Chouinard, G., Annable, L., Fontaine, R. et al. Psychopharmac. 77, 229-233 (1982).
Woodruff, G. N., Hill, D. R., Boden, P., Pinnock, R., Singh, L. & Hughes, J. Neuropeptides 19, 45-56 (1991).
Dockray, G. J. Br. Med. Bull. 38, 253-258 (1982).
Passaro, E., Debas, H., Olandorf, W. & Yamada, Y. Brain Res. 241, 335-340 (1982).
Freeman, A. S. & Chiodoi, L. A. Brain Res. 439, 266-274 (1988).
Hamilton, M. Br. J. Med. Psychol. 32, 50 (1959).
Hamilton, M. Br. J. Soc. Clin. Psychol. 6, 278-296 (1967).
The structured clinical interview for DSM II (SCID-P) Feb. 1985 version. Spitzer, R., Williams, J. & Gibbons, M. Psychometrics Division, New York State Psychiatric Institute, New York (1985).
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. E. & Erbaugh, J. K. Arch. Gen. Psychiatr. 4, 561-571 (1961).
Singh, L., Field, M. J., Hughes, J., Menzies, R., Oles, R., Vass, C. A. & Woodruff, A. N. Br. J. Pharmac. 104, 239-245 (1991).

Affiliated with

Also associated with

Rating

Blood levels of CCK peptides relative to panic disorder treatmen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Blood levels of CCK peptides relative to panic disorder treatmen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blood levels of CCK peptides relative to panic disorder treatmen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1927812